Phase II study of capecitabine and irinotecan combination chemotherapy in patients with advanced gastric cancer

被引：0
作者：
J H Baek
J G Kim
S B Jeon
Y S Chae
D H Kim
S K Sohn
K B Lee
Y J Choi
H J Shin
J S Chung
G J Cho
H Y Jung
W Yu
机构：
[1] Kyungpook National University Hospital,Department of Oncology/Hematology
[2] Pusan National University Hospital,Department of Oncology/Hematology
[3] Kyungpook National University Hospital,Department of General Surgery
来源：
British Journal of Cancer | 2006年 / 94卷
关键词：
capecitabine; chemotherapy; gastric cancer; irinotecan;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The present study was conducted to evaluate the efficacy and safety of a combination regimen of capecitabine plus irinotecan in patients with advanced gastric cancer. Patients with previously untreated metastatic or recurrent, measurable gastric cancer received oral capecitabine 1000 mg m−2 twice daily from day 1 to 14 and intravenous irinotecan 100 mg m−2 on days 1 and 8, based on a 3-week cycle. Forty-one patients were enrolled in the current study, among whom 38 were assessable for efficacy and 40 assessable for toxicity. Three complete responses and 16 partial responses were confirmed, giving an overall response rate of 46.3%. At a median follow-up of 269 days, the median time to progression and overall survival were 5.1 and 8.6 months, respectively. Grade 3/4 neutropenia occurred in four patients and grade 3 febrile neutropenia was observed in two patients. Grade 3 diarrhoea and grade 2 hand–foot syndrome occurred in six patients and eight patients, respectively. The combination of capecitabine and irinotecan was found to be well tolerated and effective in patients with advanced gastric cancer. Accordingly, this regimen can be regarded as one of first-line treatment options for advanced gastric cancer.
引用
收藏
页码：1407 / 1411
页数：4
相关论文
共 254 条
[21]  
Charnsangavej C(1999)Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer Int J Cancer 83 18-306
[22]  
Bajetta E(1995)A phase II study of capecitabine and docetaxel combination chemotherapy in patients with advanced gastric cancer Br J Cancer 71 587-297
[23]  
Di Bartolomeo M(2005)Estimates of the worldwide mortality from 25 cancers in 1990 Ann Oncol 16 1123-10
[24]  
Mariani L(2000)Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer Ann Oncol 11 301-1448
[25]  
Cassata A(2000)A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer Cancer Chemother Pharmacol 45 291-216
[26]  
Artale S(1989)Docetaxel (Taxotere)–cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO) Control Clin Trials 10 1-undefined
[27]  
Frustaci S(2003)Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients Ann Oncol 14 1442-undefined
[28]  
Pinotti G(2000)Optimal two-stage designs for phase II clinical trials J Natl Cancer Inst 92 205-undefined
[29]  
Bonetti A(2001)Capecitabine and irinotecan as first-line chemotherapy in patients with metastatic colorectal cancer: results of an extended phase I study Eur J Cancer 37 S27-undefined
[30]  
Carreca I(undefined)New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada undefined undefined undefined-undefined
12345678910